Drugs / Tetrahydrocannabivarin
last change May 2022 re-read 2 minutes ago

Tetrahydrocannabivarin

Small molecule

Developed for
hyperglycemia · hyperlipidemia · metabolic syndrome X · morbid obesity · schizophrenia · type 2 diabetes mellitus

Trials 0

Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05574049 Comparator Jan → May 2022 hyperglycemia, hyperlipidemia, metabolic syndrome X, morbid obesity Medical Life Care Planners, LLC Completed No outcome recorded
Phase 23 trials
Phase 2 NCT02053272 Comparator Feb 2014 → Feb 2016 type 2 diabetes mellitus Jazz Pharmaceuticals Completed No outcome recorded
Phase 2 NCT01491490 Comparator Oct 2011 → Oct 2012 schizophrenia GW Research Ltd Terminated No outcome recorded
Phase 2 NCT01217112 Comparator Oct 2010 → May 2012 hyperlipidemia, type 2 diabetes mellitus Jazz Pharmaceuticals Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Tetrahydrocannabivarin ClinicalTrials.gov intervention name — accepted as the source's own label NCT05574049
Known as .delta.9-tetrahydrocannabivarin ChEMBL registry synonym — accepted as the source's own label CHEMBL2387541
Known as GWP42004 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01491490
2

NCT01217112

NCT02053272

Known as O-4394 ChEMBL registry synonym — accepted as the source's own label CHEMBL2387541
Known as THCV ChEMBL registry synonym — accepted as the source's own label CHEMBL2387541
Modality Small molecule CHEMBL2387541
Route Oral “5 mg capsules, PO, BD, 91 days” NCT01217112